Genetic counseling

U.S. Carrier Screening Market to Reach USD 2.14 Billion, by 2031 at 14.4% CAGR: Allied Market Research

Retrieved on: 
Tuesday, February 14, 2023
DNA, Polymerase chain reaction, Government, Hospital, Investment, Chromosome, Diagnosis, Cystic fibrosis, DSM-IV codes, Patient, Pregnancy, National Virus Reference Laboratory, Genetic counseling, Growth, Anti-transglutaminase antibodies, Prevalence, Genetic disorder, DNA sequencing, Vaccine

PORTLAND, Ore., Feb. 14, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "U.S. carrier screening Market by Type (Expanded Carrier Screening and Targeted Disease Carrier Screening), by Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays and Others), by End User (Hospitals & Clinics, Reference Laboratories, Physician Offices and Others): Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the U.S. carrier screening industry generated $585.46 million in 2021, and is estimated to reach $2.14 billion by 2031, witnessing a CAGR of 14.4% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscapes, and competitive scenarios.

Key Points: 
  • PORTLAND, Ore., Feb. 14, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, " U.S. carrier screening Market by Type (Expanded Carrier Screening and Targeted Disease Carrier Screening), by Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays and Others), by End User (Hospitals & Clinics, Reference Laboratories, Physician Offices and Others): Opportunity Analysis and Industry Forecast, 2021-2031."
  • According to the report, the U.S. carrier screening industry generated $585.46 million in 2021, and is estimated to reach $2.14 billion by 2031, witnessing a CAGR of 14.4% from 2022 to 2031.
  • By type, the expanded carrier screening segment held the major share in 2021, accounting for more than two-fifths of the U.S. carrier screening market revenue.
  • By technology, the DNA sequencing segment accounted for the highest revenue in 2021, contributing to nearly two-fifths of the U.S. carrier screening market share.

Latest Information about Medication Safety in Breastmilk Now Easily Accessible via New LactRx App

Retrieved on: 
Wednesday, February 8, 2023
Unitary state, United States National Library of Medicine, HRSA, Vaccine, Pregnancy, Pharmacy, Health Resources and Services Administration, Office of Inspector General, U.S. Department of Health and Human Services, Organization, Korea Disease Control and Prevention Agency, University of California, San Diego, OTIS, Teratology, National library, NLM, Government, Obstetrics, Doctor of Pharmacy, HHS, Pediatrics, Health, Genetics, Nursing, Genetic counseling, Midwifery, CDC, Child, Chambers, UC, MPH, Gynaecology, Public, Birth control, Online shopping, Doctor of Philosophy

BRENTWOOD, Tenn., Feb. 8, 2023 /PRNewswire-PRWeb/ -- The non-profit Organization of Teratology Information Specialists (OTIS), through its public-facing service known as MotherToBaby, launches LactRx, a free app providing current information on the use of medications, vaccines, diagnostic agents & drugs of misuse during breastfeeding. The LactRx app provides easy access to the LactMed database, a resource from the National Library of Medicine (NLM).

Key Points: 
  • The LactRx app provides easy access to the LactMed database, a resource from the National Library of Medicine (NLM).
  • Because of this, she saw it as an opportunity for MotherToBaby to help build and host a new app with all of the LactMed information.
  • "The NLM made the decision to continue supporting web access to LactMed, and to discontinue support for its app.
  • Information presented in the LactRx app is not intended to be a substitute for professional judgment.

Global Genes Announces Completion of RARE-X Merger and Strategic Direction for Combined Organization

Retrieved on: 
Tuesday, February 7, 2023
Organization, Caregiver, Health equity, Rare disease, Kansas City metropolitan area, Diagnosis, Travel, Global Genes, Patient, Ecosystem, Research, Genetic counseling, Disease, Education, Learning, Drug discovery, Gene, Medical device, Pharmaceutical industry, Nursing

ALISO VIEJO, Calif., Feb. 7, 2023 /PRNewswire-PRWeb/ -- The rare disease patient advocacy organization Global Genes today announced it has completed its merger with the nonprofit data-sharing platform RARE-X and unveiled a three-pronged strategy for the combined organization that focuses on providing tools, connections, and opportunities to meet the needs of next-generation advocacy.

Key Points: 
  • Son Rigby said going forward, Global Genes is organizing its work around three pillars: support for patients and developing communities, educational tools, and research enablement.
  • Global Genes has a rich history of providing education and information through its toolkits, events, webinars, podcasts, and videos.
  • To help patients better address mental health issues, Global Genes is working to connect people with the most appropriate resources faster.
  • To support diversity in research, Global Genes is launching two pilot programs with partners in the Kansas City and Alabama regions.

MotherToBaby Launches First Lupus in Pregnancy Research Study

Retrieved on: 
Wednesday, February 1, 2023
Unitary state, HRSA, Vaccine, Pharmacy, SLE, Health Resources and Services Administration, Office of Inspector General, U.S. Department of Health and Human Services, Organization, Korea Disease Control and Prevention Agency, OTIS, University of California, San Diego, Teratology, Travel, Government, Belimumab, Obstetrics, HHS, Pediatrics, Health, Midwifery, Lupus, Risk, Genetics, CDC, Genetic counseling, Nursing, Chambers, Child, Lupus nephritis, UC, Pregnancy, SAN, MPH, Gynaecology, Public, Environmental science, Dietary supplement, Birth control, Doctor of Philosophy

SAN DIEGO, Feb. 1, 2023 /PRNewswire-PRWeb/ -- Recruitment is underway for a groundbreaking new study on the treatment of lupus during pregnancy. The observational research, led by world-renowned UC San Diego epidemiologist Christina Chambers, PhD, MPH, is the first of its kind for the non-profit MotherToBaby, a CDC-recommended organization that provides evidence-based information on medications, diseases, vaccines, herbal supplements and more during pregnancy and breastfeeding.

Key Points: 
  • SAN DIEGO, Feb. 1, 2023 /PRNewswire-PRWeb/ -- Recruitment is underway for a groundbreaking new study on the treatment of lupus during pregnancy.
  • The study will recruit 400 pregnant people over a five-year period to evaluate use of the lupus drug Benlysta® (belimumab) in pregnancy.
  • Benlysta® is used to treat the most common type of lupus, systemic lupus erythematosus (SLE), as well as lupus nephritis.
  • The study will be MotherToBaby's first to focus on a treatment specifically for lupus, and participants will be enrolled into the MotherToBaby Pregnancy Studies research program.

Parkinson's Foundation Global Genetics Study Hits Enrollment Milestone

Retrieved on: 
Tuesday, January 24, 2023
Parkinson's disease, University, Gene, Neurology, Diagnosis, Genetic testing, Senior counsel, Participation, Parkinson's Foundation, PD, Partnership, Observation, Research, Genetic counseling, NIH, Genetics, Dominican Republic, Parkinson, Doctor of Philosophy, Pharmaceutical industry, Palladium, MD, Physician

NEW YORK and MIAMI, Jan. 24, 2023 /PRNewswire/ -- The Parkinson's Foundation has reached a significant milestone with the recruitment, genetic testing and counseling of 7,500 participants in its international study, PD GENEration: Mapping the Future of Parkinson's Disease. Currently at 50% of its recruitment goal of 15,000, the study includes 36 participant sites, over 50 referral sites and has expanded to Canada – while still offering home testing – as part of the Foundation's commitment to increasing access to Parkinson's disease (PD) research.

Key Points: 
  • PD GENEration tests for clinically relevant genes with the goal of improving PD care by accelerating research to advance improved treatments.
  • The study helps people with PD and their physicians identify whether they qualify for enrollment in clinical trials.
  • The Foundation extensively engages Hispanics and Latinos and provides genetic counseling in English and Spanish, a first-of-its-kind for a study of this scale.
  • The study is conducted in partnership with the Parkinson Study Group under the leadership of Michael Schwarzschild, MD, PhD, and Hubert Fernandez, MD.

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market

Retrieved on: 
Tuesday, January 17, 2023
Associate, Roche, Center for Epidemiologic Studies Depression Scale, MS, Genetic counseling, Molecular epidemiology, Pancreatic cancer, Medical Affairs Bureau, Economics, Ohio State University, Diagnosis, Survival, Genomics, Engineering, Roche Diagnostics, Cancer, Doctor of Philosophy, Pharmaceutical industry, Genetics, Genetic

Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.

Key Points: 
  • Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.
  • Prior to joining Roche, she spent over 13 years in academia, most recently as a tenured Associate Professor at The Ohio State University.
  • Her lab focused on the contribution of genomics to cancer susceptibility and survival following diagnosis.
  • Lara brings expertise in designing, implementing, analyzing, and leading large-scale international clinical, biomarker, genomic and epidemiologic studies resulting in national and international scientific presentations and over 130 peer-reviewed publications.

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market

Retrieved on: 
Tuesday, January 17, 2023
Associate, Roche, Center for Epidemiologic Studies Depression Scale, MS, Genetic counseling, Molecular epidemiology, Pancreatic cancer, Medical Affairs Bureau, Economics, Ohio State University, Diagnosis, Survival, Genomics, Engineering, Roche Diagnostics, Cancer, Doctor of Philosophy, Pharmaceutical industry, Genetics, Genetic

Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.

Key Points: 
  • Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.
  • Prior to joining Roche, she spent over 13 years in academia, most recently as a tenured Associate Professor at The Ohio State University.
  • Her lab focused on the contribution of genomics to cancer susceptibility and survival following diagnosis.
  • Lara brings expertise in designing, implementing, analyzing, and leading large-scale international clinical, biomarker, genomic and epidemiologic studies resulting in national and international scientific presentations and over 130 peer-reviewed publications.

Nest Genomics Closes $8.5 Million Seed Financing to Bring Genomics into Mainstream Patient Care

Retrieved on: 
Tuesday, January 10, 2023
Technology, Finance, Consulting, Genetics, Other Technology, Health Technology, Professional Services, Software, Health, Disease, Genetic testing, Adoption of electronic medical records in U.S. hospitals, Public health, Y Combinator, American College, General partnership, Nucleic acid sequence, Polygene, Pediatrics, Scores, Genomics, American College of Medical Genetics and Genomics, Pharmacogenomics, Health, Cancer, Electronic health record, Genetic counseling, EMR, Patient, Medicine, Medical genetics, Pharmaceutical industry, Nest, Invitae

Nest is an end-to-end solution designed to help health systems, clinics, pharmaceutical companies, and payors launch and scale longitudinal genomic programs.

Key Points: 
  • Nest is an end-to-end solution designed to help health systems, clinics, pharmaceutical companies, and payors launch and scale longitudinal genomic programs.
  • The Electronic Medical Records (EMR)-integrated platform allows for the seamless incorporation of genomics into clinical practice within existing workflows, including clinical decision support to help providers create patient care plans based on the latest clinical guidelines and patient information.
  • The solution also includes patient engagement tools that empower patients to understand and manage their genetic information over time.
  • To realize this potential, we must address the major challenges of incorporating genetic information into provider workflows and patient care,” said Moran Snir, Nest Genomics Co-Founder and CEO.

Press Registration Is Now Open for the 2023 ACMG Annual Clinical Genetics Meeting

Retrieved on: 
Tuesday, January 10, 2023
American College, Sessions, Health, Gene editing, Medical genetics, ACMG, Research, Abstract (summary), Genomics, MBA, Infant, Medicine, WGS, Glycogen storage disease, Therapy, Genetics, Genetic counseling, Intelligence, Pharmaceutical industry, Antibiotics, Illumina

BETHESDA, Md., Jan. 10, 2023 /PRNewswire/ -- The 2023 ACMG Annual Clinical Genetics Meeting will be in Salt Lake City, Utah on March 14-18, 2023. This annual medical and scientific conference continues to provide groundbreaking research and the latest advances in medical genetics, genomics and personalized medicine. The 2023 ACMG Annual Clinical Genetics Meeting will offer media a firsthand look at what is shaping the future of genetics and genomics in medicine and will offer a variety of engaging and interactive educational formats and types of sessions—from Scientific Sessions and Workshops to TED-Style Talks, Case-based Sessions, Platform Presentations and Short Courses.

Key Points: 
  • Join journalists from around the world covering the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting on March 14-18, 2023
    BETHESDA, Md., Jan. 10, 2023 /PRNewswire/ -- The 2023 ACMG Annual Clinical Genetics Meeting will be in Salt Lake City, Utah on March 14-18, 2023.
  • This annual medical and scientific conference continues to provide groundbreaking research and the latest advances in medical genetics, genomics and personalized medicine.
  • Credentialed media representatives on assignment are invited to cover the ACMG Annual Meeting on a complimentary basis.
  • Abstracts will be available in March 2023 and will be published as a supplement to Genetics in Medicine Open.

JUNO DIAGNOSTICS™ EXPANDS ITS PRODUCT PORTFOLIO WITH THE LAUNCH OF JUNO HAZEL™ PLUS AND ANNOUNCES EARLY ACCESS PROGRAM (EAP) FOR INNOVATIVE NIPS TESTS

Retrieved on: 
Monday, January 9, 2023
Klinefelter syndrome, Turner syndrome, Blood, XYY syndrome, Commercial Operating System (COS), Prenatal care, Genetic testing, SAN, Phlebotomy, EAP, XXY, Pregnancy, Patient, Hazel, Edwards, Special access program, Physician, NIPT, XYY, NIPS, Trisomy, Down syndrome, Edwards syndrome, Genetic counseling, Juno, Pharmaceutical industry

Similar to the Juno Hazel™ screening test, Juno Hazel™ Plus leverages JunoDx's proprietary Sample Collection Kit to improve early access to high-quality genetic testing without the high costs, long lead times, and phlebotomy requirements of venous-based NIPS.

Key Points: 
  • Similar to the Juno Hazel™ screening test, Juno Hazel™ Plus leverages JunoDx's proprietary Sample Collection Kit to improve early access to high-quality genetic testing without the high costs, long lead times, and phlebotomy requirements of venous-based NIPS.
  • Juno Hazel™ Plus offers a comprehensive prenatal screening solution by screening for common chromosomal trisomies, sex chromosome aneuploidies, and fetal sex.
  • "The expansion of our product portfolio with the launch of our second NIPS test , Juno Hazel™ Plus, represents a significant milestone for JunoDx™.
  • To ensure every pregnancy has the opportunity to benefit from our product portfolio, the time is now to create and launch a formalized Early Access Program.